Therapeutic Areas: oncology

Cancer Is Constantly Evolving.
And So Are We.

Next-gen therapies require a new direction in the way clinical trials are conducted, creating a new and separate set of pressures to execute early-phase trials effectively.

Influence, education, and agility are more valuable now than ever before. Your success depends on choosing the right partner, and that’s where we step in.

The traditional approach falls short, especially when
less than 3% of oncology patients participate in a clinical trial,
and 82% of studies fail to meet milestones.

See how Proxima CRO's agile approach can help you

Early-phase oncology fact sheet

Do you have an early-phase oncology asset in development?

Learn how Proxima CRO is set to meet your unique needs by downloading our early-phase oncology fact sheet.

DOWNLOAD FACTSHEET

From Idea to market.

A track record of success with next-gen therapies.

Our team understands the unique needs of a successful oncology trial and how to navigate them, but most importantly, we never lose sight of the potential to ease the suffering of patients in need.

Armed with robust clinical knowledge of the continuously evolving field of oncology, Proxima's team successfully executes trials across multiple solid and liquid tumor indications. Our oncology experts each have decades of experience working at both large and emerging oncology organizations, including McKesson, US Oncology, Worldwide Clinical Trials, and MedSource.

Experience

200

Clinical Trials

FDA APPROVED DRUGS

On TIME. On Budget.

At Proxima, we pride ourselves on getting clients to every milestone while staying on budget.

Our experience with community oncology and academic sites will help you find the right patient at the right time. Our expertise also extends to regulatory submission — we can help author, review, and file your IND.

Learn More

Time to SIV

Proxima

7 Weeks

Industry

4 Months

Time to FPI post SIV

Proxima

3 Weeks

Industry

7 Weeks

Based in the Houston,Texas.

No Better Place For Oncology R&D

than the largest medical center in the world.

Texas offers oncology funding opportunities unavailable elsewhere.

CPRIT (The Cancer Prevention & Research Institute of Texas) creates and supports infrastructure that accelerates the commercialization of new cancer drugs, diagnostics, and therapies.

With over $3B dollars in funding and over 1,500 awards and counting, it is the second largest grant funding organization outside of the National Institutes of Health.

Find out how we can help advance your mission with CPRIT.

Precise executon delivers innovation

The biggest drivers of innovation aren't
big-name companies.

It's smaller, emerging companies like yours spearheading this new wave in breakthrough development.

The oncology landscape has drastically changed in the last 20 years, especially with the emergence of gene-editing and a newfound focus on the roles of immunotherapy.
‍
Developing therapies in oncology are stepping way from the general toxins of the past and creating innovative new therapies designed to target cancer cells and utilize the natural systems within the body, like the immune system, to achieve longer remissions of diseases that would have been fatal a decade ago.

Progress is happening in real-time.

We understand the challenges emerging companies face, and we’re always a step ahead, solution in hand.

Partner with an expert that understands your innovation

"The projects are very interesting as they deal a lot with niche products, and products that are seeking for a market. The people are fantastic, funny, open minded, tolerant, adorable, intelligent, competent, but above all they are motivated."

Position

First & Last Name

Position

First & Last Name

Developing medical technology for children has unique challenges. The Southwest National Pediatric Device Innovation Consortium (SWPDC) is a consortium supported by an FDA grant to assist innovators with their pediatric device development as well as address their regulatory challenges. Proxima has been a strong partner for us in helping guide innovators quickly through their regulatory and clinical journey.

Physician

Chester J. Koh, MD

Proxima has been an important piece of Memgen's regulatory and clinical achievements for multiple years now, playing a vital role in our IND approval, clinical launch, and trial management of our first-in-human study of our lead cancer immunotherapy biologic. Proxima and its growing team have continually shown their experience, broad skill sets, adaptability to our company's needs and objectives, and value in an industry with a myriad of CROs to choose from.